Literature DB >> 28449205

Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial.

M Y L Siaw1, Y Ko2,3, D C Malone4, K Y K Tsou5, Y-J Lew5, D Foo6, E Tan5, S C Chan7, A Chia6, S S Sinaram8, K C Goh5, J Y-C Lee1.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: With the increasing prevalence of diabetes, the physician-centred model is challenged to deliver holistic care in Asia. Diabetes may be managed effectively within a multidisciplinary collaborative care model; however, evidence on its effectiveness in Asian patients is lacking. Therefore, the primary objective was to evaluate the clinical outcomes of multidisciplinary collaborative care vs physician-centred care in diabetes. The secondary objectives were to evaluate humanistic and economic outcomes among the two types of care.
METHODS: This 6-month prospective, open-label, parallel-arm, randomized, controlled study was conducted at four outpatient healthcare institutions. High-risk patients aged ≥21 years with uncontrolled type 2 diabetes, polypharmacy and comorbidities were included. Patients with type 1 diabetes or those who were unable to communicate independently were excluded. The control arm received usual care with referrals to nurses and dietitians as needed. The intervention arm (multidisciplinary collaborative care) was followed up with pharmacists regularly, in addition to receiving the usual care. The primary outcomes included HbA1c, systolic blood pressure, low-density lipoprotein and triglycerides. The secondary outcomes included scores from the Problem Areas in Diabetes (PAID) and the Diabetes Treatment Satisfaction Questionnaires (DTSQ), and diabetes-related health service utilization rates and costs. RESULTS AND DISCUSSION: Of 411 eligible patients, 214 and 197 patients were randomized into the intervention and control arms, respectively. At 6 months, 141 patients in the intervention arm (65.9%) and 189 patients in the control arm (95.9%) completed the study. Mean HbA1c reduced from 8.6%±1.5% at baseline to 8.1%±1.3% at 6 months in the intervention arm (P=.04), with up to mean HbA1c improvement of 0.8% in patients with greater levels of uncontrolled glycemia. Whereas the mean HbA1c in the control arm remained unchanged (8.5%±1.4%) throughout the 6-month period. Improvements in PAID and DTSQ scores, reduction in physician workload and an average cost savings of US$91.01 per patient were observed in the intervention arm over 6 months. WHAT IS NEW AND
CONCLUSIONS: The positive clinical, humanistic and economic outcomes highlighted the value of multidisciplinary collaborative care for Asian diabetic patients, thereby supporting the effectiveness of this approach in managing chronic diseases.
© 2017 The Authors. The Journal of Clinical Pharmacy and Therapeutics Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  diabetes; outcome assessment (health care); pharmacy practice; primary care; randomized controlled trial

Mesh:

Substances:

Year:  2017        PMID: 28449205     DOI: 10.1111/jcpt.12536

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  19 in total

1.  Impact of integrating pharmacists into primary care teams on health systems indicators: a systematic review.

Authors:  Benedict Hayhoe; Jose Acuyo Cespedes; Kimberley Foley; Azeem Majeed; Judith Ruzangi; Geva Greenfield
Journal:  Br J Gen Pract       Date:  2019-09-26       Impact factor: 5.386

2.  Impact of 'Chief-Pharmacist System' on drug expenditures and rational drug use.

Authors:  Zhuo Ma; ZhiXia Zhao; ShuSen Sun; YiFan Li; ZhuoLing An; Yan Yan; LiHong Liu
Journal:  Int J Clin Pharm       Date:  2020-01-09

3.  Patients' perceptions of pharmacist-managed diabetes services in the ambulatory care and community settings within Singapore.

Authors:  Melanie Yee Lee Siaw; Jing Heng Toh; Joyce Yu-Chia Lee
Journal:  Int J Clin Pharm       Date:  2018-01-20

4.  The effectiveness of daily humanistic care in pharmaceutical care of patients with type 2 diabetes.

Authors:  Xue Hui; Zhou Yinghua; Xie Shengxiong; Zeng Qingfa; Guan Yingjun
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

5.  Medication compliance in Singaporean patients with Alzheimer's disease.

Authors:  Zheng Kang Lum; Ma Serrie P Suministrado; N Venketasubramanian; M Kamran Ikram; Christopher Chen
Journal:  Singapore Med J       Date:  2018-06-22       Impact factor: 1.858

6.  "Clearly they are in the circle of care, but . . .": A qualitative study exploring perceptions of personal health information sharing with community pharmacists in an integrated care model.

Authors:  Teagan Rolf von den Baumen; Jennifer Lake; Amanda C Everall; Katie Dainty; Zahava Rosenberg-Yunger; Sara J T Guilcher
Journal:  Can Pharm J (Ott)       Date:  2020-09-25

7.  Understandings, Attitudes, and Barriers About Diabetes Care: Analysis of Factors Influencing Community Pharmacists in China.

Authors:  Jia Wang; Yuyao Pei; Feng Yu; Zhen Kang; Yufen Zheng
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-03       Impact factor: 3.168

Review 8.  Pharmacist services for non-hospitalised patients.

Authors:  Mícheál de Barra; Claire L Scott; Neil W Scott; Marie Johnston; Marijn de Bruin; Nancy Nkansah; Christine M Bond; Catriona I Matheson; Pamela Rackow; A Jess Williams; Margaret C Watson
Journal:  Cochrane Database Syst Rev       Date:  2018-09-04

Review 9.  Interprofessional Collaboration and Diabetes Management in Primary Care: A Systematic Review and Meta-Analysis of Patient-Reported Outcomes.

Authors:  Mario Cesare Nurchis; Giorgio Sessa; Domenico Pascucci; Michele Sassano; Linda Lombi; Gianfranco Damiani
Journal:  J Pers Med       Date:  2022-04-15

10.  Efficacy of Pharmacist Based Diabetes Educational Interventions on Clinical Outcomes of Adults With Type 2 Diabetes Mellitus: A Network Meta-Analysis.

Authors:  Allah Bukhsh; Tahir M Khan; Shaun W H Lee; Learn-Han Lee; Kok-Gan Chan; Bey-Hing Goh
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.